Siemens Fonds Invest GmbH Buys Shares of 12,496 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Siemens Fonds Invest GmbH acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 12,496 shares of the biotechnology company's stock, valued at approximately $821,000.

Other institutional investors have also made changes to their positions in the company. LRI Investments LLC increased its stake in shares of BioMarin Pharmaceutical by 856.9% in the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 437 shares during the period. SBI Securities Co. Ltd. acquired a new stake in BioMarin Pharmaceutical during the fourth quarter worth about $36,000. CIBC Private Wealth Group LLC grew its position in BioMarin Pharmaceutical by 64.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock worth $41,000 after buying an additional 233 shares in the last quarter. Smartleaf Asset Management LLC grew its position in BioMarin Pharmaceutical by 111.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock worth $58,000 after buying an additional 466 shares in the last quarter. Finally, Vermillion & White Wealth Management Group LLC acquired a new stake in BioMarin Pharmaceutical during the fourth quarter worth about $62,000. 98.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on BMRN. Citigroup decreased their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Bank of America lifted their target price on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Piper Sandler lifted their target price on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a research report on Thursday, February 20th. Scotiabank lifted their target price on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 20th. Finally, Wedbush reaffirmed an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $93.45.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer now owns 14,173 shares in the company, valued at approximately $840,600.63. The trade was a 11.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 3,354 shares of company stock worth $216,269 in the last quarter. Insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Price Performance

Shares of BMRN traded down $0.56 on Friday, hitting $57.99. The company's stock had a trading volume of 2,312,260 shares, compared to its average volume of 1,873,876. The company has a market capitalization of $11.12 billion, a PE ratio of 26.36, a PEG ratio of 0.61 and a beta of 0.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The company has a 50 day moving average price of $61.08 and a 200 day moving average price of $64.49.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.